Tonix Pharmaceuticals Holding Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated February 3, 2026, discloses preliminary operating results for the year and quarter ended December 31, 2025, and financial condition information as of January 30, 2026. The Company is a biopharmaceutical firm with common stock (TNXP) trading on the NASDAQ Capital Market.
Key Financial Metrics
| Metric | Year Ended Dec 31, 2025 | Year Ended Dec 31, 2024 |
|---|---|---|
| Net Revenue | $13.1 million | $10.1 million |
| Net Loss | $118.9 million | $130.0 million |
| Net Cash Used in Operating Activities | $99.0 million | $60.9 million |
| Capital Expenditures | $3.4 million | $0.1 million |
Liquidity and Cash Position: As of December 31, 2025, the Company held approximately $207.6 million in cash and cash equivalents. As of January 30, 2026, there were 12,793,952 shares of common stock outstanding.
Material Changes
- Revenue Growth: Net revenue increased by approximately $3.0 million (29.7%) year-over-year. This includes $1.4 million in revenue from TONMYA™ sales between November 17, 2025, and December 31, 2025. Revenue from core products (Zembrace SymTouch and Tosymra) grew from $10.1 million to $11.7 million.
- Loss Reduction: Net loss decreased by approximately $11.1 million year-over-year.
- Increased Operating Burn: Net cash used in operating activities increased by $38.1 million compared to the prior year.
- Higher Capital Spending: Capital expenditures rose significantly to $3.4 million from $0.1 million in the prior year.
Outlook, Risks, and Management Commentary
Management believes current cash resources will meet planned operating and capital expenditure requirements into the first quarter of 2027. The Company expects to file its Annual Report on Form 10-K on or about March 16, 2026.
Cautionary Note: The financial data presented is preliminary, unaudited, and subject to revision. The independent registered public accounting firm, EisnerAmper LLP, has not audited or reviewed this information. Actual results may differ materially from these estimates.
Investor Verification Checklist
- Verify the final audited net loss and revenue figures in the upcoming Form 10-K (expected March 16, 2026).
- Confirm the sustainability of the $1.4 million TONMYA™ revenue run rate post-launch.
- Review the detailed breakdown of the $38.1 million increase in operating cash burn.
- Assess the specific capital expenditure projects driving the increase from $0.1 million to $3.4 million.
- Monitor cash runway updates to ensure the projection of sufficiency through Q1 2027 remains valid.